Intrinsiqq

Biotricity Inc. (BTCY) Quality Score

BTCY
Quality63

Valuation is the primary weakness (avg 45/100). Growth is the relative bright spot.

Broad-market heuristics · Not a buy/sell signal

Valuation

Growth

Earnings Multiple
0/100
-0.6x

Negative earnings, no valuation support

Cash Flow Multiple
90/100
12.1x

Under 20x cash flow, well covered

Revenue Growth
100/100
14.2%

Above 10% CAGR, strong compounder

Cash Flow Growth
60/100
Just turned +

Recently turned FCF-positive, capex cycle finishing, CAGR not yet meaningful

Business Quality & Capital Allocation

Share Dilution
0/100
166.7%

Heavy dilution above 5%

Margin Trend
100/100
+169.4pp

Expanded 3+pp, strong improvement

Capital Structure
0/100
$2M

Net debt/FCF of 10.3x, high leverage

2023
$570460
$2M
2024
$786060
$1M
2025
$365145
$3M
2026
$149789
$2M
TTM
$466503
$2M
Return on Capital
100/100
82.1%

Above 20%, exceptional capital efficiency

Customize WeightsPremiumUpgrade

Biotricity (BTCY) quality: score, margins and returns

Biotricity (BTCY) scores 63/100 on Intrinsiqq's quality score (a solid business), a weighted blend of 6 metrics each scored 0 to 100, on 9.6% operating margins and 82.1% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Biotricity (BTCY) a high-quality business?+

Biotricity scores 63 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a solid business on these measures. Recent figures include a 9.6% operating margin and a 82.1% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Biotricity's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from BTCY's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Biotricity scores well and where it falls behind.

What is Biotricity's return on invested capital (ROIC)?+

Biotricity earns about 82.1% on its invested capital, which is exceptional. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to BTCY's margins and growth on this scorecard to judge durability.

How profitable is Biotricity?+

Biotricity runs an operating margin of about 9.6% and a net margin of about -16.4%. Revenue has grown at roughly 36.4% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

SourceQuality score computed from the 10-Q filed 19 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 20 Aug 2026. How this is calculated.

Fiscal year ends Mar. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Related stocks: Surgical & Medical Instruments & Apparatus

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.